Home › Compare › MANZF vs ABBV
MANZF yields 3544.84% · ABBV yields 3.06%● Live data
📍 MANZF pulled ahead of the other in Year 1
Combined, MANZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MANZF + ABBV for your $10,000?
Manz AG engages in the manufacture and sale of high-tech equipment in Germany, the United States, Taiwan, rest of Europe, China, and internationally. The company operates in five segments: Solar, Electronics, Energy Storage, Contract Manufacturing, and Service. The Solar segment provides system solutions for thin-film solar modules and CIGS thin-film technology. The Electronics segment offers production, assembly, and handling systems for the manufacture of flat screen displays, touch sensors, printed circuit boards, chip carriers, smartphones, tablet computers, laptops, wearables, and other consumer electronics; and automated assembly solutions for the automotive industry. The Energy Storage segment offers production, assembly, and handling equipment for lithium-ion battery cells, modules, and systems, as well as for capacitors for the manufacture of consumer electronics, power electronics, and other components of electrical powertrain. The Contract Manufacturing segment provides contract manufacturing services for equipment manufacturing, parts production, and assembly works for range of industries. The Service segment offers after-sales services, such as repair and maintenance, or conversion and upgrade services for machines and assemblies. Manz AG also provides simulation and factory planning, process and prototype development, and customer training services. The company was formerly known as Manz Automation AG and changed its name to Manz AG in June 2011. Manz AG was founded in 1987 and is based in Reutlingen, Germany.
Full MANZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.